Ali Zarrin, PhD

Dr. Ali Zarrin serves as Senior Vice President of Drug Discovery at TRexBio, leading a team of scientists with the overall responsibility for target discovery, validation, and preclinical therapeutic development in different disease areas.

Dr. Zarrin joined Early Research and Development at Genentech where he was instrumental in leading several transformational initiatives to advance multiple therapeutic programs from early discovery research covering diverse mechanistic pathways for cancer, inflammatory and autoimmune indications. He also led various disease area research strategies with the focus in autoimmune and inflammatory diseases. Dr. Zarrin is an inventor on 5 patents and has over 41 scientific publications on diverse topics in journals including Nature, Nature Immunology, Nature reviews Drug Discovery, Nature Reviews Immunology, Science, Science Signaling and PNAS.

Dr. Zarrin obtained his BS in University of Minnesota and his PhD in Immunology from University of Toronto. He then carried out postdoctoral study in the lab of pioneering geneticist and molecular immunologist, Fred Alt, at HHMI/Harvard.